Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Marker genes for the lymphocyte subpopulations identified in Supplementary Figure 6. Only genes with adjusted p-value < 0.01 and average log fold-change > 0.3 were included. gene, gene name; p_val, p-value calculated based on Wilcoxon test; avg_logFC, log fold-change of the average expression between the given cluster and all other clusters; pct.1, fraction of gene-expressing cells in the given cluster; pct.2, fraction of gene-expressing cells in all other clusters; pct.diff, Difference between the percentage of gene-expressing cells in the given cluster and all other clusters; p_val_adj, Bonferroni adjusted p-value; cluster, cluster annotation based on the gene markers identified; resolution, clustering resolution parameter used in Seurat.